Drugmakers unveil cancer drug data at the ASCO annual meeting, while Amazon Pharmacy announces new features for caregivers, ...

CHICAGO -- The neurokinin-targeted agent elinzanetant significantly reduced the frequency of hot flashes among women ...

CHICAGO -- Progression-free survival (PFS) in metastatic hormone receptor (HR)-positive breast cancer more than doubled with ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...

Pivotal Phase 3 VERITAC-2 clinical trial results presented at ASCO demonstrate 2.9-month improvement in median ...

Results from the Phase III VERITAC-2 trial demonstrated that vepdegestrant reduced the risk of disease progression or death ...

CHICAGO >> Treating breast cancer patients with AstraZeneca’s experimental pill camizestrant at the first sign of resistance ...

Treating breast cancer patients with AstraZeneca's experimental pill camizestrant at the first sign of resistance to standard ...

By Julie Steenhuysen CHICAGO (Reuters) -Treating breast cancer patients with AstraZeneca's experimental pill camizestrant at ...

Breast cancer (BC) is the most prevalent cancer among women globally with two million diagnosed cases each year. Oestrogen ...

A ctDNA-guided approach can help identify when patients with HR-positive advanced breast cancer are developing an ESR1 ...

While vepdegestrant outperformed a standard treatment option in a subtype of patients, the benefit on progression-free ...